Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.
Dastgheib
Seyed Ali
SA
Mowla
Arash
A
Ghanizadeh
Ahmad
A
Khajeian
Abdul Mohammad
AM
D000374:Aggression / Q000523:psychology; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D004565:Electroconvulsive Therapy; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000523:psychology; D008607:Intellectual Disability / Q000150:complications; D000077152:Olanzapine; D010302:Parkinson Disease, Secondary / Q000139:chemically induced* / Q000517:prevention & control*; D011595:Psychomotor Agitation / Q000523:psychology; D055815:Young Adult
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine